Review
doi: 10.1128/AAC.45.8.2185-2197.2001.
Clinical and experimental advances in treatment of visceral leishmaniasis
Affiliations
- PMID: 11451673
- PMCID: PMC90630
- DOI: 10.1128/AAC.45.8.2185-2197.2001
Item in Clipboard
Review
Clinical and experimental advances in treatment of visceral leishmaniasis
Antimicrob Agents Chemother.
2001 Aug.
No abstract available
Similar articles
-
Visceral Leishmaniasis: Recent Advances in Diagnostics and Treatment Regimens.Infect Dis Clin North Am. 2019 Mar;33(1):79-99. doi: 10.1016/j.idc.2018.10.005. Infect Dis Clin North Am. 2019. PMID: 30712769 Review.
-
Visceral leishmaniasis therapy.J Chemother. 1989 Jul;1(4 Suppl):956-9. J Chemother. 1989. PMID: 16312721 No abstract available.
-
Miltefosine for visceral leishmaniasis.N Engl J Med. 2000 Mar 23;342(12):894-5. doi: 10.1056/NEJM200003233421214. N Engl J Med. 2000. PMID: 10733376 No abstract available.
-
Treatment of visceral leishmaniasis: options and choice.Lancet Infect Dis. 2016 Feb;16(2):142-3. doi: 10.1016/S1473-3099(15)00528-9. Epub 2016 Jan 26. Lancet Infect Dis. 2016. PMID: 26867454 No abstract available.
-
Visceral leishmaniasis: can we dream its eradication?J Assoc Physicians India. 2001 Jun;49:605-8. J Assoc Physicians India. 2001. PMID: 11584933 Review. No abstract available.
Cited by
-
Morphine-induced neuroimmunomodulation in murine visceral leishmaniasis: the role(s) of cytokines and nitric oxide.J Neuroimmune Pharmacol. 2007 Dec;2(4):338-51. doi: 10.1007/s11481-007-9094-y. Epub 2007 Oct 10. J Neuroimmune Pharmacol. 2007. PMID: 18040852
-
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.Antimicrob Agents Chemother. 2002 Nov;46(11):3472-7. doi: 10.1128/AAC.46.11.3472-3477.2002. Antimicrob Agents Chemother. 2002. PMID: 12384352 Free PMC article.
-
In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani.Parasitol Res. 2010 Jul;107(2):475-9. doi: 10.1007/s00436-010-1906-y. Epub 2010 May 22. Parasitol Res. 2010. PMID: 20495931
-
Pentavalent antimonials: new perspectives for old drugs.Molecules. 2009 Jun 30;14(7):2317-36. doi: 10.3390/molecules14072317. Molecules. 2009. PMID: 19633606 Free PMC article. Review.
-
Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.Antimicrob Agents Chemother. 2018 Jan 25;62(2):e01810-17. doi: 10.1128/AAC.01810-17. Print 2018 Feb. Antimicrob Agents Chemother. 2018. PMID: 29133553 Free PMC article.
References
-
- Ahuja S S, Reddick R L, Sato N, Montalbo E, Kostecki V, Zhao W, Dolan M J, Melby P C, Ahuja S K. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol. 1999;163:3890–3897. - PubMed
-
- Alexander J, Carter K C, Al-Fasi N, Satoskar A, Brombacher F. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol. 2000;30:2935–2943. - PubMed
-
- Almeida R, D'Oliveira A, Machado P, Barcellar O, Ko A I, de Jesus A R, Mobashery N, Santis J B, Carvalho E M. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis. J Infect Dis. 1999;180:1735–1737. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
